Comparison of vilanterol, a novel long-acting beta(2) agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

BACKGROUND: Current maintenance therapies for asthma require twice-daily dosing. Vilanterol (VI) is a novel long-acting beta(2) agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (ICS). Findings from a previous 4-week study suggested that VI has inherent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lötvall, Jan, Bateman, Eric D, Busse, William W, O’Byrne, Paul M, Woodcock, Ashley, Toler, William T, Jacques, Loretta, Goldfrad, Caroline, Bleecker, Eugene R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055937/
https://www.ncbi.nlm.nih.gov/pubmed/24928338
http://dx.doi.org/10.1186/1477-5751-13-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055937/
https://www.ncbi.nlm.nih.gov/pubmed/24928338
http://dx.doi.org/10.1186/1477-5751-13-9

Ejemplares similares